Business News

    Orthocell (ASX:OCC) appoints leading US surgeons to advisory board

    Article Image

    Australian regenerative medicine firm Orthocell (ASX:OCC) has appointed internationally recognised orthopaedic surgeons, Professor Christopher Dy and Professor David Brogan onto its Medical Scientific Advisory Board.

    The Professors, based at the Washington University and Barnes-Jewish Orthopedic Center, have been appointed to assist with clinical development and US market access for Orthocell’s nerve repair medical device.

    Orthocell says both surgeons bring a wealth of clinical and research expertise, including significant experience advancing pre-clinical and clinical research programs.

    It also says with these additions to the specialist advisory team, the company is ideally positioned to drive its device into the US market. 

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa